Huntington Ingalls Industries Inc vs McKesson Corporation — how do they compare? Huntington Ingalls Industries Inc trades at $270.99 (market cap $10.64B), while McKesson Corporation trades at $824.51 (market cap $97.35B). The key difference: McKesson Corporation is far larger — about 9.1× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays the higher dividend (2.04%). Which is the better fit depends on your goals.
| HII | MCK | |
|---|---|---|
Market Cap | $10.64B | $97.35B |
Sector | Technology | Health |
52-Week High | $453.73 | $995.69 |
52-Week Low | $252.93 | $659.01 |
Enterprise Value | $13.36B | $101.98B |
Dividend Yield | 2.04% | 0.39% |
Signals from Pluang's Aura AI — not financial advice
HII trades at $270.04, up 0.34% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company shows solid fundamentals with a P/E of 17.49 and ROE of 12.2%, supported by three consecutive quarterly earnings beats. Recent news highlights contract wins and shipbuilding milestones, reinforcing its defense sector presence. Cash flow improved to a net positive $49 million in 2026 from a net outflow of $57 million in 2025.
The outlook is cautiously optimistic given analyst consensus targets near $354.50, though technical resistance at $273 poses a near-term hurdle. Risks include execution delays on defense contracts and macroeconomic pressures on government spending. The stock offers value with a below-sector P/S of 0.82, but investors should monitor Q2 2026 earnings due July 30 for margin sustainability.
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Trailing returns across standard periods
Latest headlines on both assets
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →